---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-004542"
form_type: "8-K"
ticker: "PHIO"
cik: "0001533040"
company_name: "Phio Pharmaceuticals Corp."
filed_at: "2026-02-18T23:59:59+00:00"
generated_at: "2026-05-16T02:02:17.162892+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Phio Pharmaceuticals amends CEO Bitterman's contract: severance to 12 months, bonus target to 50%

## Summary
- CEO Robert J. Bitterman's severance increased to 12 months base salary on termination without cause or for good reason.
- Annual target bonus opportunity raised from 40% to 50% of base salary.
- Amendment effective Feb 17, 2026; equity vesting acceleration unchanged.
- No other changes to existing employment agreement terms.

## SEC filing metadata
- accession: 0001437749-26-004542
- form_type: 8-K
- ticker: PHIO
- cik: 0001533040
- company_name: Phio Pharmaceuticals Corp.
- filed_at: 2026-02-18T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1533040/000143774926004542/0001437749-26-004542-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1533040/000143774926004542/phio20260216_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-004542
- JSON: https://secwatch.observer/filing/0001437749-26-004542.json
- Plain text: https://secwatch.observer/filing/0001437749-26-004542.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.